Enovis Corporation
ENOV Real Time Price USDRecent trades of ENOV by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ENOV holdings by institutional investors
Quarterly net insider trading by ENOV's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$25,000 Jul 14, 2026 Issue: Budget/Appropriations Trade (domestic/foreign)
-
$40,000 Jul 14, 2026 Issue: Medicare/Medicaid
-
$25,000 Apr 20, 2026 Issue: Budget/Appropriations Trade (domestic/foreign)
-
$40,000 Apr 15, 2026 Issue: Medicare/Medicaid
-
$25,000 Jan 20, 2026 Issue: Budget/Appropriations Trade (domestic/foreign)
-
$40,000 Jan 13, 2026 Issue: Medicare/Medicaid
-
$30,000 Oct 14, 2025 Issue: Medicare/Medicaid
-
$50,000 Jul 15, 2025 Issue: Medicare/Medicaid
-
$40,000 Apr 09, 2025 Issue: Medicare/Medicaid
-
$40,000 Jan 16, 2025 Issue: Medicare/Medicaid
-
$20,000 Oct 16, 2024 Issue: Medicare/Medicaid
-
$20,000 Jul 05, 2024 Issue: Medicare/Medicaid
-
$50,000 Oct 18, 2023 Issue: Health Issues
-
$50,000 Jul 18, 2023 Issue: Health Issues
-
$50,000 Jan 19, 2023 Issue: Health Issues
-
$10,000 Oct 20, 2022 Issue: Medicare/Medicaid
-
$50,000 Oct 19, 2022 Issue: Health Issues
-
$20,000 Jul 19, 2022 Issue: Medicare/Medicaid
-
$20,000 Apr 19, 2022 Issue: Medicare/Medicaid
-
$20,000 Jan 20, 2022 Issue: Medicare/Medicaid
-
$20,000 Oct 20, 2021 Issue: Medicare/Medicaid
-
$20,000 Jul 19, 2021 Issue: Medicare/Medicaid
-
$20,000 Apr 19, 2021 Issue: Medicare/Medicaid
-
$30,000 Jan 20, 2021 Issue: Health Issues Medicare/Medicaid
-
$30,000 Oct 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jul 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$30,000 Apr 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: Medicare/Medicaid
-
$30,000 Oct 21, 2019 Issue: Medicare/Medicaid
-
$30,000 Jul 22, 2019 Issue: Medicare/Medicaid
-
$30,000 Apr 22, 2019 Issue: Medicare/Medicaid
-
$30,000 Jan 22, 2019 Issue: Medicare/Medicaid
-
$30,000 Oct 16, 2018 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2018 Issue: Medicare/Medicaid
-
$30,000 Apr 19, 2018 Issue: Medicare/Medicaid
-
$30,000 Jan 19, 2018 Issue: Medicare/Medicaid
-
$30,000 Oct 20, 2017 Issue: Medicare/Medicaid
-
$30,000 Jul 20, 2017 Issue: Medicare/Medicaid
-
$30,000 Apr 21, 2017 Issue: Medicare/Medicaid
-
$30,000 Jan 23, 2017 Issue: Medicare/Medicaid
-
$40,000 Oct 20, 2016 Issue: Medicare/Medicaid
-
$50,000 Jul 19, 2016 Issue: Medicare/Medicaid
-
$50,000 Apr 20, 2016 Issue: Medicare/Medicaid
-
$50,000 Jan 19, 2016 Issue: Medicare/Medicaid
Former government officials who have lobbied for ENOV
8 former government officials from 5 congressional offices at 2 lobbying firms have lobbied for ENOV, most recently Jul 14, 2026.
-
Gayle Gerdes Senate Legislative Correspondent: Senator Timothy Hutchison; Legislative Assistant: Congressman Chris John; Intern: Congressman Jim McCrery and Congressman Cleo Fields -
Daniel Boston House Health Policy Director, House Energy & Commerce; Deputy Chief of Staff & Spokesperson for Congresswoman Sue Kelly; Policy Advisory & Communications Director for Congressman Joe Knollenberg; Communications Advisor for Senator Mitch McConnell -
Gregory Sunstrum House New Chief of Staff , Rep. Debbie Dingell; Deputy Chief of Staff and Leg. Director, Rep. Debbie Dingell ; Leg. Director, Rep. John Dingell; Leg. Assistant, Rep. John Dingell; Staff Assistant/Leg. Correspondent Rep. John Dingell -
Zachary Pfister House New LegDir Rep Larry Kissell; SenLegAsst Rep Larry Kissell; LegAsst Rep Larry Kissell; LegCorrespondent Rep Larry Kissell; LegCorrespondent Rep Brad Ellsworth; StaffAsst Rep Brad Ellsworth; LegIntern Sen Evan Bayh -
Adam Steinmetz House New Policy Advisor - Committee on the Budget, United States House of Representatives
-
Nadeam Elshami House New CoS, Dem. Ldr Pelosi; Comms.Dir/Sr. Adv., Dem.Ldr Nancy Pelosi; Dep. Comms. Dir/Sr. Adv., Speaker Pelosi; Sr. Comms. Adv./Dep. Comms. Dir/Spokesman/Natl Press Sec, Sen Durbin; Dep. CoS/Comms Dir/Press Sec, Rep Schakowsky; Dep Press Sec, Sen Boxer -
Emily Felder Congress New Director of the Office of Legislation, CMS; Counsel, House Energy and Commerce Committee; Counsel, Senate Committee on Homeland Security and Government Affairs; Counsel, House Oversight and Government Reform Committee
-
Laura Bollier Senate New Legislative intern - Senate HELP Committee
ENOV Estimated quarterly lobbying spending
ENOV Revenue by Segment or Geography
New ENOV patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ENOV from public contracts
Recent insights relating to ENOV
Recent picks made for ENOV stock on CNBC
ETFs with the largest estimated holdings in ENOV
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ENOV stock a Buy, Sell, or Hold?
- What is the price target for $ENOV stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ENOV stock?
- Who owns the most shares of $ENOV stock?
- What funds own $ENOV stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ENOV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
- Address Lewisville, TX
- Market Cap 1.0 billion
- Employees 7,802
- Industrial Classification Orthopedic, Prosthetic & Surgical Appliances & Supplies
Enovis Corporation (ENOV) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Enovis Corporation (ENOV).
Quiver Premium charts ENOV's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ENOV, per a recent SEC DEF 14A filing. We estimate that the median employee at Enovis CORP is paid $40,725.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|